CYRX logo

Cryoport, Inc. Stock Price

NasdaqCM:CYRX Community·US$439.6m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

CYRX Share Price Performance

US$8.78
2.13 (32.03%)
US$16.00
Fair Value
US$8.78
2.13 (32.03%)
45.1% undervalued intrinsic discount
US$16.00
Fair Value
Price US$8.78
AnalystHighTarget US$16.00
AnalystConsensusTarget US$13.22
AnalystLowTarget US$8.00

CYRX Community Narratives

AnalystHighTarget·
Fair Value US$16 45.1% undervalued intrinsic discount

Digitalization And Secular Trends Will Expand Biotech Cold Chain Services

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value US$13.22 33.6% undervalued intrinsic discount

Cold Chain Expansion Will Support Cell And Gene Therapies

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value US$8 9.8% overvalued intrinsic discount

Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$16
45.1% undervalued intrinsic discount
Revenue growth
-4.24% p.a.
Profit Margin
14.21%
Future PE
35.45x
Share price in 2028
US$20.22
US$8
9.8% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-6.71% p.a.
Profit Margin
14.2%
Future PE
19.19x
Share price in 2028
US$10.12

Updated Narratives

CYRX logo

Cold Chain Expansion Will Support Cell And Gene Therapies

Fair Value: US$13.22 33.6% undervalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CYRX logo

Rising Biopharma Regulations Will Crimp Expansion But Foster Recovery

Fair Value: US$8 9.8% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
CYRX logo

Digitalization And Secular Trends Will Expand Biotech Cold Chain Services

Fair Value: US$16 45.1% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and fair value.

1 Risk
2 Rewards

Cryoport, Inc. Key Details

US$243.8m

Revenue

US$133.0m

Cost of Revenue

US$110.8m

Gross Profit

US$171.5m

Other Expenses

-US$60.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.21
45.45%
-24.89%
36.3%
View Full Analysis

About CYRX

Founded
1999
Employees
1098
CEO
Jerrell Shelton
WebsiteView website
www.cryoportinc.com

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions’ Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Recent CYRX News & Updates

Recent updates

No updates